[1] Ranjbary AG, Mehrzad J, Dehghani H, Abdollahi A, Hosseinkhani S.Variation in Blood and Colorectal Epithelia’s Key Trace Elements Along with Expression of Mismatch Repair Proteins from Localized and Metastatic Colorectal Cancer Patients, Biol Trace Elem Res. 2019; doi: 10.1007/s12011-019-01749-9.
[2] Willett CG, Chang DT, Czito BG, Meyer J, Wo J. Oncology scan-gastrointestinal cancers
Int J Radiat Oncol Biology Phys. 2013; 87: 861-3.
[3] Pietsch EC, Sykes SM, McMahon SB, Murphy ME. The p53 family and programmed cell death. Oncogene. 2008;27:6507-21.
[4] Ma BB, Poon TC, To KF, Zee B, Mo FK, Chan CM, Ho S, Teo PM, Johnson PJ, Chan AT. Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma—a prospective study. Head & Neck 2003;25:864-72.
[5] Wong NA, Mayer NJ, MacKell S, Gilmour HM, Harrison DJ. Immunohistochemical assessment of Ki67 and p53 expression assists the diagnosis and grading of ulcerative colitis‐related dysplasia. Histopathology. 2000;37:108-14.
[6] Ahmad R, Alam M, Hasegawa M, Uchida Y, Al-Obaid O, Kharbanda S, Kufe D. Targeting MUC1-C inhibits the AKT-S6K1-elF4A pathway regulating TIGAR translation in colorectal cancer. Mol Cancer. 2017;16:33.
[7] Matsuo T, Komatsu M, Yoshimaru T, Kiyotani K, Miyoshi Y, Sasa M, Katagiri T. Involvement of B3GALNT2 overexpression in the cell growth of breast cancer. Int J Oncol. 2014; 44:427-34.
[8] Raina D, Agarwal P, Lee J, Bharti A, McKnight CJ, Sharma P, Kharbanda S, Kufe D. Characterization of the MUC1-C cytoplasmic domain as a cancer target. PLoS One. 2015;10(8):e0135156.
[9] Gastinel LN, Bignon C, Misra AK, Hindsgaul O, Shaper JH, Joziasse DH. Bovine α1, 3‐galactosyltransferase catalytic domain structure and its relationship with ABO histo‐blood group and glycosphingolipid glycosyltransferases. EMBO J. 200;20:638-49.
[10] Torre LA, Bray F, Siegel RL, Ferlay J, Lortet‐Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87-108.
[11] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7-30.
[12] Den Uil SH, Coupé VM, Linnekamp JF, Van Den Broek E, Goos JA, Delis-van Diemen PM, Eric J, Van Grieken NC, Scott PM, Vermeulen L, Medema JP. Loss of KCNQ1 expression in stage II and stage III colon cancer is a strong prognostic factor for disease recurrence. Br J Cancer. 2016;115:1565-71.
[13] Mundade R, Imperiale TF, Prabhu L, Loehrer PJ, Lu T. Genetic pathways, prevention, and treatment of sporadic colorectal cancer. Oncoscience. 2014;30:400-6.
[14] Dolatkhah R, Somi MH, Bonyadi MJ, Asvadi Kermani I, Farassati F, Dastgiri S. Colorectal cancer in Iran: molecular epidemiology and screening strategies. J Cancer Epidemiol. 2015;643020.
[15] Sparreboom CL, van Groningen JT, Lingsma HF, Wouters MWJM, Menon AG, Kleinrensink GJ, Jeekel J, Lange JF; Different Risk Factors for Early and Late Colorectal Anastomotic Leakage in a Nationwide Audit. Dis Colon Rectum. 2018; 61:1258-66.
[16] Safaee A, Moghimi-Dehkordi B, Fatemi SR, Pourhoseingholi M, Ghiasi S, Zali MR. Colorectal cancer in Iran: an epidemiological study. Asian Pac J Cancer Prev. 2008;9:123-6.
[17] Aimee S J, Veronica R, Jean S W, Enola K, Graham A. Colditz Systems intervention to promote colon cancer screening in safety net settings: protocol for a community-based participatory randomized controlled trial. Implement Sci. 2013;8:58-65.
[18] Tanjani PT, Motlagh ME, Nazar MM, Najafi F. The health status of the elderly population of Iran in 2012. Arch Gerontol Geriatr. 2015;60:281-7.
[19] Danial Z, Motamedi M, Mirhashemi S, Kazemi A, Mirhashemi AH. Aging in Iran. Lancet. 2014;384(9958):1927.
[20] Rafiemanesh H, Pakzad R, Abedi M, Kor Y, Moludi J, Towhidi F, Makhsosi BR, Salehiniya H. Colorectal cancer in Iran: Epidemiology and Morphology Trends. EXCLI J. 2016;15:738-44.
[21] Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3:1101-8.
[22] Unver A, Felek S, Paddock CD, Zhi N, Horowitz HW, Wormser GP, Cullman LC, Rikihisa Y. Western blot analysis of sera reactive to human monocytic ehrlichiosis and human granulocytic ehrlichiosis agents. J Clin Microbiolo. 2001;39:3982-6.
[23] Lee KS, Kwak Y, Ahn S, Shin E, Oh HK, Kim DW, Kang SB, Choe G, Kim WH, Lee HS. Prognostic implication of CD274 (PD-L1) protein expression in tumor-infiltrating immune cells for microsatellite unstable and stable colorectal cancer. Cancer Immunol Immunother. 2017;66:927-39.
[24] Meysamie A, Ghaletaki R, Haghazali M, Asgari F, Rashidi A, Khalilzadeh O, et al. Pattern of tobacco use among the Iranian adult population: results of the national Survey of Risk Factors of Non-Communicable Diseases (SuRFNCD-2007). Tob Control. 2010;19:125-8.
[25] Dolatkhah R, Somi MH, Kermani IA, Ghojazadeh M, Jafarabadi MA, Farassati F, Dastgiri S. Increased colorectal cancer incidence in Iran: a systematic review and meta-analysis. BMC Public Health. 2015;15:1-14.
[26]Ghoncheh M, Mohammadian M, Mohammadian-Hafshejani A, Salehiniya H. The incidence and mortality of colorectal cancer and its relationship with the human development index in Asia. Ann Glob Health. 2016; 82:726-37.
[27]Chen J, Lin Y, Zhang R, Huang ZJ, Pan XG. Contribution of NAD(P)H quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and risk of colorectal adenoma and colorectal cancer in Caucasians: a meta-analysis. Arch Med Res. 2012;43:55-66.
[28]Sobhani I, Amiot A, Le Baleur Y, Levy M, Auriault ML, Van Nhieu JT, Delchier JC. Microbial dysbiosis and colon carcinogenesis: could colon cancer be considered a bacteria-related disease? Therap Adv Gastroenterol. 2013;6:215-29.
[29] Siegel R, DeSantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014;64:104-17.
[30] Navabi SJ, Beiranvand B, Pournia Y, Izadi B, Hosseini J, Obeidavi Z, Nasiri B, Rahbar S. Epidemiology of colorectal cancer in patients admitted to Imam Reza hospital in Kermanshah from 2006 to 2011. Basic Clin Cancer Res. 2012;27:2-7.
[31] Sabiston D.C, Lyerly H.K. Text book of surgery 16th ed .Philadelphia. W. B Saunders Co. 2001;961-9. doi: 10.1002/9780470757819.
[32] Mansori K, Solaymani-Dodaran M, Mosavi-Jarrahi A, Motlagh AG, Salehi M, Delavari A, Asadi-Lari M. Spatial Inequalities in the Incidence of Colorectal Cancer and Associated Factors in the Neighborhoods of Tehran, Iran: Bayesian Spatial Models. J Prev Med Public Health. 2018;51:33-6.
[33] Shadmani FK, Ayubi E, Khazaei S, Sani M, Hanis SM, Khazaei S, Soheylizad M, Mansori K. Geographic distribution of the incidence of colorectal cancer in Iran: a population-based study. Epidemiol Health. 2017;17: 1-13.
[34] Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 2009;22:191-7.
[35] Hoseini S, Moaddabshoar L, Hemati S, Mohammadianpanah M. An overview of clinical and pathological characteristics and survival rate of colorectal cancer in Iran. Ann Colorectal Res. 2014;2:e17264.
[36]Yoosefi M, Baghestani AR, Khadembashi N, Pourhoseingholi MA, Baghban AA, Khosrovirad A. Survival Analysis of Colorectal Cancer Patients Using Exponentiated Weibull Distribution. Int J Cancer Management. 2018;11:1-6.
[37] Wang L, Liu Z, Fisher KW, Ren F, Lv J, Davidson DD, Baldridge LA, Du X, Cheng L. Prognostic value of programmed death ligand 1, p53, and Ki-67 in patients with advanced-stage colorectal cancer. Hum Pathol. 2018;71:20-9.
[38] Limsui D, Vierkant RA, Tillmans LS, Wang AH, Weisenberger DJ, Laird PW, Lynch CF, Anderson KE, French AJ, Haile RW, Harnack LJ. Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. J Natl Cancer Inst. 2010;102:1012-22.
[39] Peppone LJ, Hyland A, Moysich KB, Reid ME, Piazza KM, Purnell JQ, Mustian KM, Morrow GR. Examining the association between cigarette smoking and colorectal cancer using historical case-control data. Cancer Epidemiol. 2009;33:182-8.
[40] Byrd JC, Bresalier RS. Mucins and mucin binding proteins in colorectal cancer. Cancer Metast Rev. 2004;23:77-9.
[41] Bu X-D, Li N, Tian X-Q, Li Li, Jin-Song Wang, Xiao-Jin Yu, and Pei-Lin Huang. Altered expression of MUC2 and MUC5AC in progression of colorectal carcinoma. World J Gastroenterol. 2010;16:4089-94.
[42] Jing X, Liang H, Hao C, Yang X, Cui X. Overexpression of MUC1 predicts poor prognosis in patients with breast cancer. Oncol Rep. 2019;41(2):801-10.
[43] Khanh DT, Mekata E, Mukaisho K-I, et al. Transmembrane mucin MUC1 overexpression and its association with CD10+ myeloid cells, transforming growth factor-β1 expression, and tumor budding grade in colorectal cancer. Cancer Sci. 2013;104:958-64.
[44] Almaraz RT, Tian Y, Bhattarcharya R, Tan E, Chen SH, Dallas MR, Chen L, Zhang Z, Zhang H, Konstantopoulos K, Yarema KJ. Metabolic flux increases glycoprotein sialylation: implications for cell adhesion and cancer metastasis. Mol Cell Proteomics. 2012;11:M112 017558.
[45] Ju T, Aryal RP, Kudelka MR, Wang Y, Cummings RD. The Cosmc connection to the Tn antigen in cancer. Cancer Biomark. 2014;14:63-81.
[46] Peixoto A, Relvas-Santos M, Azevedo R, Santos LL, Ferreira JA. Protein glycosylation and tumour microenvironment alterations driving cancer hallmarks. Front Oncol. 2019;9:380.
[47] Ogawa T, Hirohashi Y, Murai A, Nishidate T, Okita K, Wang L, Ikehara Y, Satoyoshi T, Usui A, Kubo T, Nakastugawa M. ST6GALNAC1 plays important roles in enhancing cancer stem phenotypes of colorectal cancer via the Akt pathway. Oncotarget. 2017;8:112550.
[48] Nath S, Mukherjee P. MUC1: a multifaceted oncoprotein with a key role in cancer progression. Trends Mol Med. 2014;20:332-42.
[49] Hu M, Lan Y, Lu A, Ma X, Zhang L. Glycan-based biomarkers for diagnosis of cancers and other diseases: Past, present, and future. Prog Mol Biol Transl Sci. 2019;162:1-24.
[50] Park JH, Katagiri T, Chung S, Kijima K, Nakamura Y. Polypeptide N-acetylgalactosaminyltransferase 6 disrupts mammary acinar morphogenesis through O-glycosylation of fibronectin. Neoplasia (New York, NY). 2011;13:320.
[51] Hiruma T, Togayachi A, Okamura K, Sato T, Kikuchi N, Kwon YD, Nakamura A, Fujimura K, Gotoh M, Tachibana K, Ishizuka Y. A novel human β1, 3-N-acetylgalactosaminyltransferase that synthesizes a unique carbohydrate structure, GalNAcβ1-3GlcNAc. J Biol Chem. 2004;279:14087-95.
[52] Matsuo T, Komatsu M, Yoshimaru T, Kiyotani K, Miyoshi Y, Sasa M, Katagiri T. Involvement of B3GALNT2 overexpression in the cell growth of breast cancer. Int J Oncol. 2014;44:427-34.
[53] Johnson K, Bertoli M, Phillips L, Töpf A, Van den Bergh P, Vissing J, Witting N, Nafissi S, Jamal-Omidi S, Łusakowska A, Kostera-Pruszczyk A. Detection of variants in dystroglycanopathy-associated genes through the application of targeted whole-exome sequencing analysis to a large cohort of patients with unexplained limb-girdle muscle weakness. Skeletal Muscle. 2018;8:23.
[54] Sysel AM, Valli VE, Bauer JA. Immunohistochemical quantification of the cobalamin transport protein, cell surface receptor and Ki-67 in naturally occurring canine and feline malignant tumors and in adjacent normal tissues. Oncotarget. 2015;6:2331.
[55] Yuan JP, Wang LW, Qu AP, Chen JM, Xiang QM, Chen C, Sun SR, Pang DW, Liu J, Li Y. Quantum dots-based quantitative and in situ multiple imaging on ki67 and cytokeratin to improve ki67 assessment in breast cancer. PloS One. 2015;10:e0122734.